New website is here!
Create an account to use the new features. Feel free to leave us feedback, constructive criticism welcome!

Australian Primary Hemp Ltd (aph) Logo

Australian Primary Hemp Ltd (APH)

___:___ · AUD
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

APH Chart

APH's Principal Activity is the produces, manufactures and distributes a range of hemp products under the Australian Primary Hemp brand, to retail, wholesale and white label customers in Australia. APH engages across the hemp value chain, encompassing hemp seed selection, farming, processing, packaging as well as distribution and sale of bulk and retail products.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) +193.20%
vs ASX 200 (1yr) +193.38%

Size

Market Capitalisation
ASX Rank 1633 of 2,466
Sector Rank 60 of 75

Key Information

Shares Issued
Sector Consumer Defensive
Similar Companies AHF / AS1 / FOD
EPS -$0.109
DPS $0.00
NTA per share $0.04

Broker Consensus

APH is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Company Overview

Australian Primary Hemp Limited (APH, formerly Alchemia Limited) is a producer, manufacturer and distributor of premium plan-based and wellness products. The Group operates in Australia and engages across the hemp value chain, encompassing hemp seed selection, farming, processing, packaging as well as distribution and sale of bulk and retail products.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office South Melbourne VIC 3205
Website www.ausprimaryhemp.com.au
Registry Link Market Services
Auditor Grant Thornton Audit Pty Ltd
Date Listed 23 Dec 2003

Upcoming Calendar

Date Event
28/01/2021 Issued Shares
26/02/2021 Report (Interim)
25/08/2021 Report (Prelim)
25/08/2021 Report (Annual)

Dividend History

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Neale Joseph Chief Executive Officer, Managing Director Mar 2020 Director Bio icon

Mr Neale Joseph

Chief Executive Officer, Managing Director

Mr Joseph joined APH as Head of Product in January 2020. Neale has experience in FMCG, pharmacy, B2B distribution, procurement, and operations to the APH Board. In his previous CEO roles, Neale has led businesses across Australia, New Zealand, Asia Pacific, and the Middle East. Prior to joining APH, Neale co-founded a start-up in the natural health and beauty industry where he grew distribution to retailers in Australia, New Zealand, Canada, the United States, and Europe.

Mr James Hood Executive Director, Chief Operating Officer Oct 2019 Director Bio icon

Mr James Hood

Executive Director, Chief Operating Officer

Mr Hood have experience in production facility development and an network of farmers, which has positioned Australian Primary Hemp well to produce a complete vertically integrated product line. Prior to Australian Primary Hemp, Mr Hood had roles in agriculture, subsea engineering and digital software development.

Ms Pauline Therese Gately Non-Executive Director, Non-Executive Chairman Oct 2019 Director Bio icon

Ms Pauline Therese Gately

Non-Executive Director, Non-Executive Chairman

Ms Gately has experience across a range of portfolio of Board positions. Pauline brings a commercial focus to strategy and risk. She embraces dynamic business environments and has knowledge of navigating changing directional points. Her experience spans IPO through acquisitions and mergers. During her investment banking career, Pauline held senior positions with CitiBank, BNP International, Merrill Lynch, and Deutsche Bank. She served as a non-executive director and subsequently executive chairperson of Alliance Mineral Assets Limited (SGX: 40F) from 2011 through to December 2018. She is also member of Risk Committee.

Mr Cameron Petricevic Non-Executive Director Jun 2018 Director Bio icon

Mr Cameron Petricevic

Non-Executive Director

Mr Petricevic has spent over 15 years in the financial industry, with roles at AXA Asia Pacific Holdings (now AMP) and Acorn Capital. Cameron has investment banking experience, including valuations, mergers and acquisitions, and portfolio management. Cameron is a director of Kentgrove Equity Partners Pty Ltd and several private businesses. Cameron is Founder/Treasurer of Brimbank ToRCH, a Royal Children's Hospital auxiliary charity. He is member of the Risk Committee.

Dr Tracie Ramsdale Non-Executive Director May 2018 Director Bio icon

Dr Tracie Ramsdale

Non-Executive Director

Dr Ramsdale following a successful career as a Principal Investigator and Commercial Manager of the Centre for Drug Design and Development at the University of Queensland, Tracie co-founded Alchemia Limited, a drug discovery and development company and served as the company's CEO for almost 10 years. During this time, she was responsible for multiple financing transactions and licensing the company's technology to international pharmaceutical and manufacturing partners. Dr Ramsdale has served on a number of industry and government advisory groups and provided independent consulting advice to the biotechnology industry, academia and government. Tracie is a Fellow of the Australian Academy of Technological Sciences and Engineering, and a Member of the Australian Institute of Company Directors.

Ms Melanie Jaye Leydin Chief Financial Officer, Company Secretary Apr 2016 Director Bio icon

Ms Melanie Jaye Leydin

Chief Financial Officer, Company Secretary

Ms Leydin graduated from Swinburne University in 1997, became a Chartered Accountant in 1999 and since February 2000 has been the principal of LeydinFreyer. The practice provides outsourced company secretarial and accounting services to public and private companies specialising in ASX listed entities. Melanie has over 25 years experience in the accounting profession and has experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, reorganisation of Companies and shareholder relations.

Dr Melvyn John Bridges Non-Executive Director Sep 2015 Director Bio icon

Dr Melvyn John Bridges

Non-Executive Director

Dr Bridges has over 35 years experience founding and building international lifescience, diagnostic and medical device companies and commercialising a range of Australian technology. He is in charge for commercial and M&A transactions and liquidity events, including listings on the ASX. He has founded and had develop medical device and diagnostic companies, including Pacific Diagnostics (acquired by Baxter), PanBio Ltd (acquired by Inverness Medical). He was a director of Tissue Therapies Ltd (March 2009 to December 2015), Benitec BioPharma Limited (October 2007 to June 2014) and Anatara Lifesciences Ltd (until May 2018). He serves as a member of the Risk Management Committee.

Mr David Lamm Executive Chairman, Executive Director Jul 2015 Director Bio icon

Mr David Lamm

Executive Chairman, Executive Director

Mr Lamm has over 16 years of experience in business and financial markets including roles at Credit Suisse, Bain & Company and the Alter Family Office. He is the founder and Managing Director of Kentgrove Capital. He is the Chairman of Investment Committee.

Peter Smith N/A
Charles Mann N/A
Timothy Hughes N/A
Carlo Montagner N/A
Susan Kelley N/A
Darren Book N/A
Nathan Drona N/A

Director Transactions

APH directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
22/10/20 Pauline Gately Issued 334,000 $0.18 $60,120 Issue of options
22/10/20 Cameron Petricevic Issued 334,000 $0.18 $60,120 Issue of options
21/10/20 James Hood Issued 2,280,000 $0.18 $410,400 Issue of securities
18/11/19 Charles Mann Buy +249,020 $0.201 $50,043 On-market trade
14/11/19 Charles Mann Buy +657 $0.18 $118 On-market trade
11/11/19 Charles Mann Buy +4,494 $0.18 $809 On-market trade
02/10/19 Cameron Petricevic Issued 1,216,904 $0.011 $13,386 Issue of securities
02/10/19 Cameron Petricevic Issued 4,196,500 $0.011 $46,162 Issue of securities

Director Interests

The current holdings of APH directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Pauline Gately 22/10/2020 50,000 N/A 334,000 N/A
Cameron Petricevic 22/10/2020 N/A 4,999,999 1,550,904 N/A
James Hood 21/10/2020 N/A 7,600,000 5,369,231 N/A
Neale Joseph 08/10/2020 N/A 33,896 N/A N/A
Melanie Leydin 02/10/2019 0 125,000 N/A N/A

Shareholder Info

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Aug 19, 2020.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
CIA Mann Family Pty Ltd 8,543,671 12.25%
HSBC Custody Nominees (Australia) Limited 5,499,786 7.88%
James Robert Hood Pty Ltd 5,320,000 7.63%
TTOR Pty Ltd 4,999,999 7.17%
Mutual Trust Pty Ltd 3,250,000 4.66%
Crofton Park Development Pty Ltd 2,736,667 3.92%
Jasforce Pty Ltd 2,350,000 3.37%
CG Nominees (Australia) Pty Ltd 2,000,000 2.87%
Shomron Pty Ltd 1,971,338 2.83%
Sem Patterson Pty Ltd 1,540,000 2.21%
LD Fifty Ltd 1,250,000 1.79%
Cassa Trading Pty Ltd 1,227,435 1.76%
Brittany Pty Ltd 1,100,000 1.58%
Mr Ashley James Hardwick 1,100,000 1.58%
Peter Johnson & Kim Johnson 1,100,000 1.58%
NA Investments (Vic) No 2 Pty Ltd 1,100,000 1.58%
Stepheno Holdings Pty Ltd 971,022 1.39%
Citicorp Nominees Pty Limited 671,106 0.96%
Kent Street Capital No. 2 Pty Ltd 650,000 0.93%
Okulicz Pty Ltd 640,661 0.92%

Shareholder Distribution

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 3,367 564 191 268 64 4,454

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held under multiple names so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Name Last Notice Total Shares Shares Held (%)
HSBC Custody Nominees (Australia) Limited 19/08/2020 5,499,786 7.88
TTOR Pty Ltd 19/08/2020 4,999,999 7.17
CIA Mann Family Pty Ltd 21/10/2020 11,550,000 15.14
James Robert Hood Pty Ltd 21/10/2020 7,600,000 9.96
Wexford Rise Pty Ltd 23/09/2020 4,525,000 6.52

Shareholders Buying

Date Name Bought Previous % New %
21-10-20 James Robert Hood Pty Ltd 2,280,000 7.70 9.96
21-10-20 CIA Mann Family Pty Ltd 3,465,000 11.60 15.14
23-09-20 Wexford Rise Pty Ltd -- -- 6.52

Shareholders Selling

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $0.11 30 June
Page Icon
APH Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.